Mutations in PTPRD, CREBBP, BRAF, NOTCH3, TERT, and SETD2, which are involved in various aspects of immune regulation, were reported as potential biomarkers in cancer patients after immunotherapy with improved survival (Ackerman et al., 2014; Ortiz et al., 2014; Li et al., 2020; Lin et al., 2020; Lu et al., 2021; Yan et al., 2021; Zhang et al., 2022). The gene discussed is SETD2; the disease is cancer.